Restricted accessOtherFirst published online 2008-4
Relationship of Linezolid Minimum Inhibitory Concentration and Time to Bacterial Eradication in Treatment for Methicillin-Resistant Staphylococcus Aureus Infection
SteinkrausG, WhiteR, FriedrichL. Vancomycin MIC creep in non–vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J Antimicrob Chemother2007; 60: 788-94.
3.
AndesD, van OgtropML, PengJ. CraigWA. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother2002; 46: 3484-9.
4.
GeeT, EllisR, MarshallG, et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother2001; 45: 1843-6.
5.
MoisePA, ForrestA, BirminghamMC, SchentagJJ. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother2002; 50: 1017-26.
